Current Events

You are currently browsing the archive for the Current Events category.

Tags:

Tags:

Antibiotics such as penicillin have helped to fight numerous diseases such as syphilis, and infections caused by staphylococci and streptococci.  However, overuse of antibiotics is a problem.  Physicians sometimes prescribe antibiotics to fight viral infections even though antibiotics are only effective against bacterial infections.  Because of this overuse, more and more strains of drug-resistant bacteria are appearing.  The Economist estimates that drug-resistant bacteria cost Europe alone €1.5 billion per year in health care cost and lost productivity.

Creating new antibiotics to fight drug-resistant bacteria is one of the most important challenges facing mankind.  Drug companies, however, are less enthusiastic about producing these types of drugs.  Patients take drugs for chronic diseases for a lifetime; drugs for antibiotics are usually only taken for a few week.  ”Between 1983 and 1992 American regulators approved 30 new antibiotics. Since 2003 they have approved just seven.”  Funding drug research for antibiotics, however, could change these priorities.

In the fight against drug-resistant bacteria, Europe is leading the way.  On May 8th the European Commission and Europe’s pharmaceutical association gave details of a plan to boost antibiotics research by up to €590m ($760m).

Will the U.S. match the European initiative with similar funding levels? Only time will tell.

Tags: ,

Governor Chris Christie vetoes a bill today that would form have created a health exchange in New Jersey.

“While I appreciate the Legislature’s attempt to find steady policy footing in these shifting legal sands, I am concerned that a hastily created exchange in New Jersey will impose unnecessary obligations upon the state’s citizens,” Christie said in his veto message. “I believe the better course of action … is to continue to monitor the ever-changing landscape surrounding the implementation of the Affordable Care Act, and to refrain from imposing its mandates upon our citizens until outstanding issues are settled.”

Will ObamaCare ever be implemented?  And if so, what provisions will be implemented in which states?  This is an open question that will not come close to being resolved until the Supreme Court makes its decision on the constitutionality of the Affordable Care Act.

Tags:

Joe Paduda has some interesting points:

requiring insurers accept all applicants is favored by most Republicans (according to Politico) but a) some senior Republicans hate the idea and b) there’s zero consensus re how to actually make that work. Do they forbid upcharging for older/sicker people? Adopt some form of risk-adjustment and/or financial transfer among/between insurers based on the risk profile of their members? Or allow the free market to operate, hoping that insurers will somehow figure out how to insure people with pre-existing conditions at affordable rates?

One option–an individual mandate–is certainly off the table for Republicans.  So the question is, if you want to prohibit insurers for varying premiums based on your health condition, how do you prevent premiums from skyrocketing or insurers acting illegally to avoid certain types of enrollees.  The answer to this question is not a simple one in the political realm.

Tags: ,

Tags:

Plus…

Tags: ,

Many recent healthcare policies aim to consolidate the provision of medical services.  For instance, Accountable Care Organizations consolidate providers with the goal of providing seamless, integrated patient care.  Consolidation can increase efficiency and (potentially) drive down prices.  If a market is highly concentrated, however, problems in a single supplier can lead to shortages.  Consider the case of Sandoz in Quebec.

On March 4 a fire broke out at a Quebec manufacturing facility of the multinational generic drug manufacturer Sandoz. The fire halted production and led to medication shortages across the country….

The resulting shortage has hit hospitals especially hard because the Sandoz plant manufactures the vast majority of injectable medications used in Canada….But why was one factory manufacturing such a large proportion of so many important drugs?

Hospitals in Ontario purchase most of their drugs through group purchasing organizations (GPOs). The two largest GPOs in Ontario are Medbuy and HealthPRO. Both organizations are governed by their member organizations, which are mainly hospitals and other health care providers. GPOs were established to increase efficiency for member hospitals. Instead of each hospital signing its own contracts with multiple different pharmaceutical companies, GPOs deal with the pharmaceutical companies and the hospitals only have to deal with GPOs.

GPOs drive down prices by buying in bulk. But the downside of negotiating aggressively is that sometimes only one manufacturer remains willing to supply a particular drug at the negotiated price. And what appears to have occurred in Canada is that Sandoz was the only willing manufacturer not just for one important medication, but for dozens.

There are parallels in the car industry as well.

The company is a chemical plant in a town called Marl. That explosion there killed two people. It was a tragedy, but did not seem to have global significance….Until car companies realized that Marl is vital to their business….

In [Marl], there’s a plant that makes a chemical…that is used in another material called Nylon-12, which is a material that is used – it’s a very basic material. It’s simply a coating that’s used in some of the critical parts of the vehicle, like fuel lines and brake lines.

It’s the kind of thing where it’s so specialized, that not a lot of companies make the product, but a lot of companies end up using it. The plant is one of very few – less than a handful – that make the chemical in the world.

Concentrating production in a single company can produce economies of scale.  A lack of diversification of suppliers (whether its suppliers of medications or car parts) make producers vulnerable to disruptions in their global supply chain.

Tags: , , , ,

On Monday, the World Bank announced that its new president would be American Jim Yong Kim.

Unlike previous World Bank Presidents, who typically have economics, finance or business backgrounds, Kim is a physician who built his reputation developing public health programs for poor countries.

Not everyone likes the decision.

A physician with a doctorate in anthropology, Kim was criticized by some development professionals concerned that his narrow expertise was wrong for such a diverse institution. The bank offers loans and grants to the poorest nations and pursues an array of projects in better-developed nations as well — from helping fund power plants and other infrastructure to helping countries strengthen their financial markets and government institutions.

Nigeria is unhappy that their candidate, Nigerian Finance Minister Ngozi Okonjo-Iweala, was not chosen.

[Analyst for the African Center for Leadership, Strategy and Development Otive] Igbuzor said in a phone interview that without providing a greater role to emerging economies, the World Bank risked irrelevance — and a threat that in future those economies could form their own development bank.

What should be Kim’s first course of action?  Take a look at the opinions from guest posts at the Guardian and the Financial Times.

Tags: ,

« Older entries